XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO® in other ASEAN markets including Thailand and Indonesia with…